Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organon & Co.OGN · Entity 4115 | Chief Commercial Officer | September 03, 2024 | September 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organon & Co.
Report date September 03, 2024 · Filed September 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,113 |
Ending reported balance
After 2024-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-03 · Grant · Acquired 3,594 · Balance 54,258 F1: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Row 2 · 2024-09-03 · Tax withholding · Disposed 1,145 · Balance 53,113 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,145 | $20.35 | $23,300.75 |
DisclosureSEC source: 0001821825-24-000095 · wk-form4_1725568236.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,113 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC | Organon & Co. OGN · Entity 4115 | GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000095 · wk-form4_1725568236.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,258 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000063 · wk-form4_1715112389.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,989 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,589 | $19.61 | $31,160.29 |
DisclosureSEC source: 0001821825-24-000063 · wk-form4_1715112389.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,664 Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000063 · wk-form4_1715112389.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 7,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000050 · wk-form4_1712184132.xml · derivative · entry 6 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,590 Underlying: Common Stock · 7,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F3 · derivative.expiration_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000050 · wk-form4_1712184132.xml · derivative · entry 5 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,772 Underlying: Common Stock · 4,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:42 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,483 | $18.80 | $46,680.40 |
DisclosureSEC source: 0001821825-24-000050 · wk-form4_1712184132.xml · nonDerivative · entry 4 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,264 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 7,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000050 · wk-form4_1712184132.xml · nonDerivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:42 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,520 | $18.80 | $28,576.00 |
DisclosureSEC source: 0001821825-24-000050 · wk-form4_1712184132.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,953 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 18:42 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000050 · wk-form4_1712184132.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 119,825 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000028 · wk-form4_1712089623.xml · derivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,825 Underlying: Common Stock · 119,825 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:27 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 29,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000028 · wk-form4_1712089623.xml · derivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,255 Underlying: Common Stock · 29,255 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 19,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000006 · wk-form4_1709328157.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,827 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 6,316 | $18.04 | $113,940.64 |
DisclosureSEC source: 0001821825-24-000006 · wk-form4_1709328157.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,702 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 19,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000006 · wk-form4_1709328157.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028099 · doc4.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,989 Underlying: Common Stock · 4,984 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:43 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,588 | $24.24 | $38,493.12 |
DisclosureSEC source: 0001209191-23-028099 · doc4.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,191 Read SEC document |
| May 04, 2023 Filed May 8, 2023 18:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028099 · doc4.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 2,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027172 · doc4.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,168 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:06 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,019 | $24.63 | $25,097.97 |
DisclosureSEC source: 0001209191-23-027172 · doc4.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,795 Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 2,168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-027172 · doc4.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 83,969 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · derivative · entry 5 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,969 Underlying: Common Stock · 83,969 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 23,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · derivative · entry 4 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,384 Underlying: Common Stock · 23,384 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,543 Underlying: Common Stock · 4,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,520 | $23.09 | $35,096.80 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,646 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:17 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023077 · doc4.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 17:27 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 9,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014835 · doc4.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,116 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 17:27 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,286 | $25.09 | $107,535.74 |
DisclosureSEC source: 0001209191-23-014835 · doc4.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,395 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 17:27 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 9,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014835 · doc4.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| May 04, 2022 Filed May 5, 2022 20:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056627 · tm2214603-3_4seq1.xml · derivative · entry 6 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,984 Underlying: Common Stock · 4,984 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F3 · derivative.exercise_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. F3 · derivative.expiration_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. Read SEC document |
| May 04, 2022 Filed May 5, 2022 20:47 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,944 | $32.44 | $63,063.36 |
DisclosureSEC source: 0001104659-22-056627 · tm2214603-3_4seq1.xml · nonDerivative · entry 4 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,565 Read SEC document |
| May 04, 2022 Filed May 5, 2022 20:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-056627 · tm2214603-3_4seq1.xml · nonDerivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056627 · tm2214603-3_4seq1.xml · derivative · entry 5 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,579 Underlying: Common Stock · 1,579 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.expiration_date: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:47 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 743 | $32.08 | $23,835.44 |
DisclosureSEC source: 0001104659-22-056627 · tm2214603-3_4seq1.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,525 Read SEC document |
| May 03, 2022 Filed May 5, 2022 20:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,579 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-056627 · tm2214603-3_4seq1.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 01, 2022 Filed May 3, 2022 19:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 2,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055428 · tm2214297-3_4seq1.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,168 Underlying: Common Stock · 2,168 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 19:39 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,019 | $32.33 | $32,944.27 |
DisclosureSEC source: 0001104659-22-055428 · tm2214297-3_4seq1.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,689 Read SEC document |
| May 01, 2022 Filed May 3, 2022 19:39 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 2,168 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055428 · tm2214297-3_4seq1.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:05 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 44,091 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042357 · tm2211465-3_4seq1.xml · derivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,091 Underlying: Common Stock · 44,091 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 18:05 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 14,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042357 · tm2211465-3_4seq1.xml · derivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,314 Underlying: Common Stock · 14,314 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 8,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029458 · tm228175-6_4seq1.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,718 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:47 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 4,098 | $37.57 | $153,961.86 |
DisclosureSEC source: 0001104659-22-029458 · tm228175-6_4seq1.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,540 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 8,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029458 · tm228175-6_4seq1.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 17:09 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033672 · doc4.xml · derivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 115,980 | $0.00 Strike: $36.11 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 13 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,980 Underlying: Common Stock · 115,980 shares Expires 2031-05-03 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 50,862 | $0.00 Strike: $36.91 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 12 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,862 Underlying: Common Stock · 50,862 shares Expires 2030-04-30 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F11 · derivative.exercise_date: 16,954 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 35,646 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 11 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,646 Underlying: Common Stock · 35,646 shares Expires 2029-05-02 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F10 · derivative.exercise_date: 23,763 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 46,215 | $0.00 Strike: $27.44 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 10 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,215 Underlying: Common Stock · 46,215 shares Expires 2028-05-03 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 45,039 | $0.00 Strike: $30.40 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 9 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,039 Underlying: Common Stock · 45,039 shares Expires 2027-05-04 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.